A unique business model for success: in-license, add value through innovative R&D strategy and implementation, out-license and maximise commercialisation potential.
We are a highly focused group of companies that develops drugs and therapies with a view to bringing novel biopharmaceuticals to market.
Our business strategy is to create partnerships for the in-licensing of biologics and small molecules from biotechnology and pharmaceutical companies as well as academic institutions worldwide.
We develop the products while paving the way to global registration and we carefully select optimal marketing partners to maximise commercialisation. ^
Enhancing the development process of biopharmaceuticals
We bring together more than 30 years of expertise and dedicated multidisciplinary teams to achieve timely regulatory and market driven pharmaceutical development programs. Our experience has been validated by the rapid development and out-licensing of five commercially successful products that are top performers in their specific therapeutic areas; Eloxatin®/Elplat®, three different formulations of Decapeptyl®/Pamorelin®/Trelstar® and Moapar®/Salvacyl®.
By maximising the commercial potential of all our partnered therapeutic products, we are not only able to share in the success with our partners and the inventors, but also to reinvest the commercial proceeds into the development of a new generation of products and partnerships.
